Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Avanos Medical ( (AVNS) ) has shared an update.
On August 1, 2025, Avanos Medical appointed David Pacitti as a Board member and Scott Galovan as the Senior Vice President, Chief Financial Officer. The company reported a 1.9% increase in net sales for the second quarter of 2025, but faced a net loss of $76.8 million due to a $77.0 million goodwill impairment charge. Despite challenges, Avanos showed growth in its Specialty Nutrition Systems and Pain Management & Recovery segments, with strategic divestitures and restructuring efforts aimed at strengthening its market position.
The most recent analyst rating on (AVNS) stock is a Hold with a $20.00 price target. To see the full list of analyst forecasts on Avanos Medical stock, see the AVNS Stock Forecast page.
Spark’s Take on AVNS Stock
According to Spark, TipRanks’ AI Analyst, AVNS is a Neutral.
Avanos Medical’s overall stock score is primarily influenced by its financial challenges and bearish technical indicators. Despite some strong segment performances highlighted in the earnings call, the company’s valuation and potential earnings impacts from tariffs and declining product lines weigh heavily on its prospects.
To see Spark’s full report on AVNS stock, click here.
More about Avanos Medical
Avanos Medical, Inc. operates in the medical device industry, focusing on life-sustaining Specialty Nutrition Systems and opioid-sparing Pain Management & Recovery segments. The company is committed to advancing its strategic segments and recently divested its Hyaluronic Acid product line to align with its transformation priorities.
Average Trading Volume: 460,860
Technical Sentiment Signal: Sell
Current Market Cap: $507.8M
Find detailed analytics on AVNS stock on TipRanks’ Stock Analysis page.